New treatments targeting known oncogenes, or growth factors, in pancreatic cancer such as K-Ras, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR) have mostly failed and do not provide survival benefits [5,6]. This evidence concerns the gene EGF and familial pancreatic carcinoma.